Clinical trial NCT05566834: Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer
Official title: A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Paclitaxel in Patients With Advanced Gastric Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Gastric Cancer
Keywords: Gastric Cancer
Lead sponsor: Minneamrita Therapeutics LLC
Sponsor class: INDUSTRY
First posted: 2022-10-04
Enrollment: 36
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Minnelide™ is a water soluble disodium salt variant of triptolide, a diterpenoid, an HSP70 inhibitor. Studies using orthotopic pancreatic cancer cell lines and human xenograft transplants demonstrate that Minnelide™ prevents tumor progression, increases survival, and causes tumor regression.
Primary purpose: TREATMENT

Brief summary: A Phase 1, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ Capsules given alone or in combination with paclitaxel in patients with Advanced Gastric Cancer.

Detailed description: Minnelide™ is a water soluble disodium salt variant of triptolide, a diterpenoid, an HSP70 inhibitor. Studies using orthotopic pancreatic cancer cell lines and human xenograft transplants demonstrate that Minnelide™ prevents tumor progression, increases survival, and causes tumor regression.

Eligibility criteria: Inclusion Criteria:

* Patients with histologically confirmed advanced gastric cancer

  * Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy
  * One or more metastatic tumors measurable per RECIST v1.1 Criteria
  * Karnofsky performance ≥ 70%
  * Life expectancy of at least 3 months
  * Age ³ 19 years
  * Signed, written IRB-approved informed consent
  * A negative pregnancy test (if female)
  * Acceptable liver function:

    * Bilirubin 1.5 times upper limit of normal
    * AST (SGOT), ALT (SGPT) and Alkaline phosphatase 2.5 times upper limit of normal (if liver metastases are present, then 5 x ULN is allowed)
    * Albumin ≥ 3.0 g/dL
  * Acceptable renal function:

    o Serum creatinine within normal limits, OR calculated creatinine clearance ³ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
  * Acceptable hematologic status:

    * Granulocyte

      * Monotherapy: ³ 1,500 cells/mm3
      * Combination therapy with paclitaxel: ³ 2,000cells/mm3 Platelet count ³ 100,000 (plt/mm3)
    * Hemoglobin ³ 9 g/dL
  * Urinalysis:

    o No clinically significant abnormalities
  * Acceptable coagulation status:

    * PT ≤ 1.5 times institutional ULN
    * PTT ≤ 1.5 times institutional ULN
  * Women of child- bearing potential and men must agree to use adequate contraception For men and women of child-producing potential, the use of effective contraceptive methods during the study and until 90 days after the last dose of IP for men or until 6 months after the last dose of IP for women or 6 months after the last dose of IP with paclitaxel for both men and women.

Exclusion Criteria:

New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

* Baseline QTc exceeding 470 msec (using the Bazett's formula) and/or patients receiving class 1A or class III antiarrhythmic agents.
* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
* Pregnant or nursing women. NOTE: For men and women of child-producing potential, the use of effective contraceptive methods during the study and until 90 days after the last dose of IP for men or until 6 months after the last dose of IP for women or 6 months after the last dose of IP with paclitaxel for both men and women. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Treatment with radiation therapy (local therapy, non-target lesion, 2 weeks), major surgery, chemotherapy, biological agents or investigational therapy within 3 weeks prior to study treatment.
* Unwillingness or inability to comply with procedures required in this protocol
* Known infection with HIV, hepatitis B, or hepatitis C
* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
* Patients who are currently receiving any other investigational agent
* Patients who are on a prohibited medication (section 4.3.2).
* Patients with biliary obstruction and/or biliary stent (Regimen B only)
* Patients with a history of severe hypersensitivity reactions to products containing Cremophor® EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate). • Patient with baseline ANC\<1500/mm3

Primary outcomes:
measure: To determine any increase of treatment emergent adverse events when Minnelide capsules are given in combination with paclitaxel.
timeFrame: 24 months
Secondary outcomes:
measure: Pharmacokinetics of Minnelide when given with paclitaxel
timeFrame: 24 months
measure: Plasma levels of Minnelide when given with paclitaxel
timeFrame: 24 months
Other outcomes:
Locations:
city: Soeul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Minneamrita Therapeutics LLC
name: Mohana Velagapudi
role: STUDY_DIRECTOR
References: